Roche Pharmaceuticals Site Visit

1
Roche PharmaceuticalsSite Visit

• Michelle Miranda
• Phil Campanella
• Chris Horvath
• October 26, 2007

2
Roche at a Glance

• Founded in 1896 in Basel, Switzerland
• Employing 74,000 people
• Core businesses pharmaceuticals diagnostics
• Leading supplier of medicines for cancer
  transplantation, and a market leader in virology
• World leader in in-vitro diagnostics
• Alliances with autonomous partners who share
  similar strategic focus (Genentech, Chugai, 80
  licensing partners)
• Ambitious and innovative strategy focused on
  personalized medicine

3
Strong Growth in Pharmaceutical Division
4
Roche U.S. Presence
5
Looking Ahead

• Among the top 10 pharmaceutical companies
  worldwide
• World market leader in oncology
• Leading in transplantation and virology
• Number one in Diagnostics
• Number one in Diabetes Care
• Number one in Biotechnology

6
Personalized Medicine A New Era in Healthcare

• Leveraging its diagnostic capabilities, and
  strategic partners
• Transition away from one size fits all, and
  trial and error healthcare
• Personalized medicine promises to save lives and
  reduce the overall cost of healthcare

7
Products
Unique HIV drug attacks the virus before it
infects T cells
Immunosuppressant medication for transplant
patients
Treatment and prevention of flu
Anti-emetic for chemotherapy and radiotherapy
patients
8
Treatment of postmenopausal osteoporosis
Treatment of Hepatitis C
Antiviral agent for treatment of CMV retinitis
Oral chemotherapy for colorectal cancer and
metastatic breast cancer
Chronic phase CML, Hairy cell Leukemia, Hepatitis
C
9

• Antiviral drug treatment- not a vaccine
• 2006 Sales of 2627m CHF
• -2 Sales Growth YTD Q3 2007
• Patent protected until 2016
• Only oral antiviral medication recommended by the
  CDC for 2007-2008 flu season

10
In August 2005 Roche donated a rapid response
stockpile of 3 million treatment courses of
Tamiflu to be used to contain or slow the spread
of a pandemic at its site of origin. This was
in addition to 125,000 courses of therapy donated
by Roche in 2004 which was used by the WHO in
affected countries in Asia. In January 2006
Roche announced the donation of a further 2
million treatment courses, or 20 million doses,
of Tamiflu to the WHO for the establishment of
regional stockpiles for use in the management of
the current avian influenza strain or in the
event of a pandemic. These donations will result
in a total of 5.125 million treatment courses
being available to the WHO to help people
affected by a potential pandemic. In 2005 and
2006 Roche donated 15,000 packs to Turkey and
2400 packs to Romania following the emergence of
the H5N1 avian influenza virus in birds in these
countries.
11
Pipeline-Roche AG

• Currently, over 100 Products
• Areas include ( products)
• Hematology Nephrology (1)
• Inflammatory, Autoimmune Bone (9)
• Cardiovascular Metabolic (8)
• Neurological Psychiatric (7)
• Oncology (13)
• Respiratory (1)
• Viral Other Infectious Disease (6)
• Opt-In Opportunities (23)
• Participation through Chugai (4)

12
Pipeline-Partnerships

• Pipeline includes 22 partner companies
• Biogen Idec (biotech)
• Novartis (pharma)
• Amgen (biotech)
• ArQule (biotech)

13
Sep 2007
14
Pipeline Trends

• Emerging Areas
• Diabetes Targets
• GLP-1
• DDP-IV
• Metabolism Target
• CETPcholesterol

15
Current News

• Med Ad News names Roche as Company of the Year
• International Serious Adverse Events Consortium
• New CEO effective Spring, 2008 for Roche AG

16
Current News

• New Disease Biology Areas (DBA) Model
• Oncology (separate from Genentech portfolio)
• Virology
• Inflammation
• Metabolism
• Central Nervous System
• Personalized Medicine

17
Current News

• Roche Vs. Amgen Anemia (ESAs)
• Mircera (R), Epogen (A), Aranesp (A)
• Anemia Treatment CKD with Dialysis
• Anemia Market 7bn./yr (since 1989-25bn)
• Mircera Approved in Europe Japan
• Oct 23/07 Amgen patents ruled valid
• FDA approval for Mircera expected November, 2007

18
Sources Cited

• Roche YTD Sept. 2007 report
• NYTimes.com
• RocheUSA.com
• FiercePharma.com

19
Schedule for Tomorrow
20
Speakers
Jay Pittampalli RBS 2007 VP of Alumni
Relations, Pharma Management Club VP of
SGA Interned at Roche Interactive
Marketing Analyst, Tamiflu Market Analytics
Business Strategy Mary Graves (Pharma
Partnering Disease Biology Area Leader) Chris
Schneider (Business Development Manager)